Schistosomiasis, also known as snail fever and bilharzia, is a disease caused by parasitic flatworms called schistosomes. The urinary tract or the intestines may be infected. Signs and symptoms may include abdominal pain, diarrhea, bloody stool, or blood in the urine. Those who have been infected a long time may experience liver damage, kidney failure, infertility, or bladder cancer. In children, it may cause poor growth and learning difficulty.
The global average price of Drugs for Schistosomiasis is in the decreasing trend, from 62 USD/K Units in 2011 to 57 USD/K Units in 2015. With the situation of global economy, prices will be in decreasing trend in the following five years.
The classification of Drugs for Schistosomiasis is Praziquantel, Oxamniquine and other. Praziquantel is the mainly drug for Schistosomiasis, and the proportion of Praziquantel in 2015 is about 90%.
Drugs for Schistosomiasis are widely used in S. haematobium, S. mansoni, S. japonicum, S. mekongi and S. intercalatum.Most of human infections are caused by S. haematobium, S. mansoni, S. japonicum. And the market share used in S. haematobium in 2015 is 28%. And the market share used in S. mansoni in 2015 is 48%.
According to this study, over the next five years the Drugs for Schistosomiasis market will register a 5.6% CAGR in terms of revenue, the global market size will reach US$ 100 million by 2024, from US$ 70 million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Drugs for Schistosomiasis business, shared in Chapter 3.
This report presents a comprehensive overview, market shares, and growth opportunities of Drugs for Schistosomiasis market by product type, application, key manufacturers and key regions and countries.
This study considers the Drugs for Schistosomiasis value and volume generated from the sales of the following segments:
Segmentation by product type: breakdown data from 2014 to 2019, in Section 2.3: and forecast to 2024 in section 11.7.
Praziquantel
Oxamniquine
Other
Segmentation by application: breakdown data from 2014 to 2019, in Section 2.4: and forecast to 2024 in section 11.8.
S. haematobium
S. mansoni
S. japonicum
S. mekongi
S. intercalatum
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
Shin Poong
Merck
Bayer
EIPICO
Chandra Bhagat Pharma
Taj Pharmaceuticals
...
In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.
Research objectives
To study and analyze the global Drugs for Schistosomiasis consumption (value & volume) by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
To understand the structure of Drugs for Schistosomiasis market by identifying its various subsegments.
Focuses on the key global Drugs for Schistosomiasis manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Drugs for Schistosomiasis with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Drugs for Schistosomiasis submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
